Product logins

Find logins to all Clarivate products below.


Narcolepsy | Treatment Algorithms | Claims Data Analysis | US

A number of therapies from a range of drug classes are available to address the symptoms of narcolepsy including excessive daytime sleepiness and cataplexy.  Our Treatment Algorithms research leverages national patient-level claims data to explore the use of key therapies in narcolepsy, such as modafinil, armodafinil, and Xyrem, in both newly diagnosed and recently-treated patients. These data provide important information regarding the patient journey in narcolepsy including treatment duration, switch patterns, and persistence and compliance by drug.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed narcolepsy patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed narcolepsy patients?
  • Where has Xyrem been integrated into the treatment algorithm?
  • What proportion of narcolepsy patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
  • What percentage of narcolepsy patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with narcolepsy?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Related Market Assessment Reports

Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…